Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of Waterloo

$21,000.00

Pluronic-based nanoparticles as novel DNA transfection vectors

FY 2013-14

Summary
Gene therapy has enormous potential as a treatment for any number of diseases in human health, both genetic and/or aquired in nature, where a correct copy of a defective or missing gene can be delivered to a cell to restore normal function. However, in order for this potential to be realized significant advancements must be made with respect to the drug delivery systems used to delivery genetic information. Currently, the most effective delivery systems are based upon viruses, and take advantage of the virus' inherent ability to infect cells, delivering DNA. Unfortunately there are very real saftey concerns surrounding the use of viral based systems, these systems can cause sudden and severe immune responses that have been linked to patient deaths in clinical trials. An alternative approach is to use self-assembling particles that are capable of binding DNA and delivering it into the cells. These non-viral systems are typically based upon positively charged lipids or polymers, and are generally non-immunogenic and have low toxicities; however, they also suffer from low efficiency in terms of DNA delivery. Our work is focused on the design of new non-viral delivery systems based upon neutral polymers that are non-toxic, are easily cleared from the body, and are biodegradable in the environment. The goal of our work is to apply our newly designed delivery systems to a gene therapy treatment for ovarian cancer, which is now the fourth leading cause of all cancer-related deaths.
Program
Discovery Grants Program - Individual
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
355626-2011
Name nom
Wettig, Shawn
Department département
Pharmacy, School of
Organization id
33
Institution établissement
University of Waterloo
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2011
Award amount
21000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
1800
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Chemical engineering
Research subject fr
Génie chimique
Partie
3
Nb partie
5
Application title
Pluronic-based nanoparticles as novel DNA transfection vectors
Keyword
NSERC
Application summary
Gene therapy has enormous potential as a treatment for any number of diseases in human health, both genetic and/or aquired in nature, where a correct copy of a defective or missing gene can be delivered to a cell to restore normal function. However, in order for this potential to be realized significant advancements must be made with respect to the drug delivery systems used to delivery genetic information. Currently, the most effective delivery systems are based upon viruses, and take advantage of the virus' inherent ability to infect cells, delivering DNA. Unfortunately there are very real saftey concerns surrounding the use of viral based systems, these systems can cause sudden and severe immune responses that have been linked to patient deaths in clinical trials. An alternative approach is to use self-assembling particles that are capable of binding DNA and delivering it into the cells. These non-viral systems are typically based upon positively charged lipids or polymers, and are generally non-immunogenic and have low toxicities; however, they also suffer from low efficiency in terms of DNA delivery. Our work is focused on the design of new non-viral delivery systems based upon neutral polymers that are non-toxic, are easily cleared from the body, and are biodegradable in the environment. The goal of our work is to apply our newly designed delivery systems to a gene therapy treatment for ovarian cancer, which is now the fourth leading cause of all cancer-related deaths.